CLDX Celldex Therapeudics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLDX Celldex Therapeudics

CLDX 23.83

-3.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (8)	12/26/2018 10:23:23 PM
From: scaram(o)uche	of 105

>> Durable complete response (CR) with CDX-3379 and cetuximab in a patient with previous cetuximab-refractory HPV- HNSCC << Monotherapy with CDX-3379......... >> • Phosphorylated ErbB3 decreased in post-treatment tumor samples for 10/12 (83%) patients • 11/12 (92%) patients experienced RECIST stable disease pre-resection • Exceptional clinical response: one patient with large, fungating floor-of-mouth tumor experienced 92% shrinkage of primary tumor by physical exam, with marked improvement in pain and ability to eat << Plus evidence of activity (PR) in melanoma together with a B-raf inhibitor in a patient who failed a second B-raf inhibitor. Results of the first stage of the phase II (n=13, HPV negative, PD-1 refractive unless not eligible) are due 1Q19, and a documented PR has been observed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next